Evaluation of contemporary echocardiographic and histomorphology parameters in predicting mortality in patients with endomyocardial biopsy-proven cardiac AL amyloidosis

Front Cardiovasc Med. 2023 Jan 24:9:1073804. doi: 10.3389/fcvm.2022.1073804. eCollection 2022.

Abstract

Introduction: This study examined the role of echocardiographic and cardiac histomorphology parameters in predicting mortality in patients with cardiac AL amyloidosis.

Methods: Patients with endomyocardial biopsy-proven cardiac AL amyloidosis treated at MD Anderson Cancer Center between 6/2011 and 6/2020 were identified. Stored echocardiographic images and endomyocardial biopsy samples were processed for myocardial strain analysis and a detailed histomorphology characterization.

Results: Of 43 patients; 44% were women and 63% white. Median age was 65 years; 51% underwent stem cell transplantation (SCT). Thirty patients (70%) died during follow up (median follow up: 4.1 years). Lower LA strain (<13.5%) and absence of SCT as a time-varying covariate were significantly associated with increased risk of death in the multivariate cox regression analysis. Higher LV mass and lower RV tricuspid annular plane systolic excursion were associated with increased odds of having ≥5% interstitial amyloid deposition on biopsy in the multivariate logistic regression analysis.

Conclusion: Lower LA strain independently predicted mortality in our cohort, and its performance in the routine assessment of AL amyloidosis may be beneficial. Furthermore, SCT for cardiac AL amyloidosis was associated with improved OS. These findings need to be confirmed by larger studies in the era of contemporary systemic therapies.

Keywords: cardiac AL amyloidosis; echocardiography; histomorphology; left atrial strain (LA strain); mortality; pathology; stem cell transplant (SCT).

Grants and funding

The statistical analysis work was supported in part by the Cancer Center Support Grant (NCI Grant P30 CA016672). EK was supported in part by NIH/NCI 1RO1HL157273 and by CPRIT RP200381. AD was supported in part by the Ting Tsung and Wei Fong Chao Distinguished Chair. NP was a Cancer Prevention Research Institute of Texas (CPRIT) Scholar and Andrew Sabin Family Foundation Fellow. NP was supported by CPRIT RP200670 and by NIH/NCI 1P01CA261669-01.